• Globe Newswire

Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases

Globenewswire -

• Globe Newswire

Boehringer Ingelheim initiates Phase II study of BI 1815368, a potential first-in-class oral treatment for diabetic macular edema

Globenewswire -

• Globe Newswire

Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia